Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-736-9 | CAS number: 2149571-40-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Link to relevant study records
- Endpoint:
- two-generation reproductive toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 11 February 2013 - 12 July 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study performed according to OECD Guideline and in compliance with GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Species:
- rat
- Strain:
- other: Crl: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: reputable commercial supplier
- Age at study initiation: ca 71 days old
- Weight at study initiation: Males: 336-390 g; Females: 234-284 g;
- Fasting period before study: no
- Housing: Cages comprised of a polycarbonate or polypropylene body with a stainless steel mesh lid; changed at appropriate intervals.
Solid (polycarbonate) bottom cages were used during the acclimatisation, pre-pairing, gestation, littering and lactation periods.
Polypropylene cages with a grid bottom were used during pairing. These were suspended above absorbent paper which was changed daily.
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 6 days before commencement of treatment
ENVIRONMENTAL CONDITIONS
- Temperature (°C) and Humidity (%): Monitored and maintained within the range of 19-23 ºC and 40-70 %.
- Air changes (per hr): Filtered fresh air which was passed to atmosphere and not recirculated.
- Photoperiod (hrs dark / hrs light): Artificial lighting, 12 hours light : 12 hours dark
IN-LIFE DATES: From: 18th February 2013 To: 05th May 2013 - Route of administration:
- oral: gavage
- Vehicle:
- other: 0.1% Tween 80
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Justification for use and choice of vehicle (if other than water): vehicle assessed in preliminary study and used for other animal testing studies
- Concentration in vehicle: 0.1%
- Amount of vehicle (if gavage): 10 mL/kg
- Lot/batch no. (if required): N/a
- Purity: As supplied - Details on mating procedure:
- - M/F ratio per cage: 5/5 (during pre-pairing) and 1/1 (during pairing)
- M/F ratio per cage: 5/5 (during pre-pairing) and 1/1 (during pairing)
- Length of cohabitation: up to two weeks
- Proof of pregnancy: Ejected copulation plugs. sperm in vaginal smear referred to as day 1 of pregnancy
- After successful mating each pregnant female was caged (how): one female per cage - Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- once daily
- Details on study schedule:
- Duration of treatment
F0 animals
Males - for a minimum of four weeks, including 15 days before pairing.
Females - for 15 days before pairing until Day 6 after birth of the
F1 generation.
F1 animals No direct treatment - Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Control
- Dose / conc.:
- 60 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Dose / conc.:
- 600 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- Three groups, each comprising ten male and ten female
- Control animals:
- yes, concurrent vehicle
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no signs associated with dosing and no general clinical signs related to treatment.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- Treatment up to 600 mg/kg/day was well tolerated, with no adverse effects on general condition or signs related to treatment. One female treated at 600 mg/kg/day was killed for
welfare reasons as it displayed signs of distress, had abdominal distension and was bleeding from the vagina. Macroscopic examination revealed that parturition had been incomplete with
two dead fetuses, two live fetuses and four placentae present in the uterus. This was considered to be the result of an unfortunate normal biological event and not related to
treatment. - Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- It was considered that there was no treatment related effect on body weight gain or food consumption on adult males or females during the two-week pre-mating period and no effect
on body weight during gestation or early lactation (to Day 7 post-partum). Males treated at 60, 200 or 600 mg/kg/day had low mean body weight gain during the week after pairing and
females receiving 600 mg/kg/day had marginally low food consumption during the first week of treatment and marginally high food consumption was seen in treated females during
gestation (Days 10-13); however, they were considered not to be toxicologically significant. - Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- It was considered that food consumption was not affected by treatment, during the two week pre-pairing period, or during gestation or lactation.
Food consumption of females treated at 600 mg/kg/day was marginally low (X 0.87 Control) during the first week of treatment and was marginally high in treated females during gestation
(Days 10-13 only), when compared with Control, but these incidences were considered to be un-related to treatment. - Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no changes observed in the reproductive organs which were considered to be related to treatment with MTF.
The seminiferous tubules of the testes were evaluated with respect to their stage in the spermatogenic cycle and the integrity of the various cell types present within the different
stages. No cell or stage specific abnormalities were noted. Two males treated at 600 mg/kg/day had pale areas on the liver and the liver of another male
was enlarged. Histopathological investigation revealed centrilobular hypertrophy, which was considered to be an adaptive change resulting from exposure to the test substance. - Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Description (incidence and severity):
- A higher proportion of females had regular cycles of 4/5 days than expected at 600 mg/kg/day, when compared with Control. The reason for this finding is not known, but as other
investigations for reproductive performance were not affected by treatment, it was considered not to represent an adverse effect of treatment. - Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Pre-coital interval, mating performance and fertility were not affected by treatment. One Control animal (No. 42) was not pregnant and had no sign of any implantations pre and post staining.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 600 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- body weight and weight gain
- food consumption and compound intake
- organ weights and organ / body weight ratios
- gross pathology
- histopathology: non-neoplastic
- reproductive function (oestrous cycle)
- reproductive performance
- Key result
- Critical effects observed:
- no
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Clinical signs recorded for the offspring identified occasional pups with findings, but the type of findings (i.e. cold to touch, bruised muzzle) and incidence were typical of post-natal
offspring and showed no relationship to treatment. - Mortality / viability:
- no mortality observed
- Description (incidence and severity):
- There was no effect of treatment on litter size, offspring survival or sex ratio.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- The slightly higher body weight gain of offspring between Days 1 and 4 of age, following parental treatment at 200 or 600 mg/kg/day, was attributed to the marginally low gains seen
in the Control and low dose group (60 mg/kg/day), which was attributed to the higher than expected mean litter size in these groups. - Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Histopathological findings:
- not specified
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 600 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- viability
- clinical signs
- body weight and weight gain
- gross pathology
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- It is concluded that once daily oral administration of MTF to male and female Crl:CD(SD) rats for at least four weeks at doses of 60, 200 or 600 mg/kg/day was well tolerated with no
effect of treatment on reproductive performance, including mating performance, fertility and offspring survival and development up to Day 7 of age.
For reproductive/developmental toxicity the no-observed-adverse-effect-level (NOAEL) was considered to be 600 mg/kg/day.
Reference
offspring, or macroscopic change in the offspring.
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 600 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The available study was conducted according to OECD test guidelines and in compliance with GLP; it should be noted that this is only a screening study and the results cannot be considered as reliable as those derived through a full reporoductive toxicity study.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 600 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The available study was conducted according to OECD test guidelines and in compliance with GLP; it should be noted that this is only a screening study and the results cannot be considered as reliable as those derived through a full reporoductive toxicity study.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
